p16INK4a is a useful marker of human papillomavirus integration allowing risk stratification for cervical malignancies

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 469-472

  Cheah, Phaik Leng ^a   Looi, Lai Meng ^a   Teoh, Kean Hooi ^a   Mun, Kein Seong ^a   Nazarina, Abdul Rahman ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Cervix; High risk human papillomavirus; Invasive squamous carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ARTICLE; CANCER GRADING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; METABOLISM; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VAGINA SMEAR;

BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84866454407     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.469     Document Type: Article

References (23)

1. Benevolo M, Mottolese M, Marandino F, et al (2006). Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol, 19, 384-91.
2. Bergeron C, Ordi J, Schmidt D, et al (2010). Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol, 133, 395-406.
3. Cheah PL, Looi LM, Sivanesaratnam V (2011). Human papillomavirus in cervical cancers of Malaysians. J Obstet Gynaecol Res, 37, 489-95
4. Cheah PL, Looi LM, Mun KS, Nazarina AR, Teoh KH (2011). Implications of continued upregulation of p16INK4a through the evolution from high-grade squamous intraepithelial lesion to invasive squamous carcinoma of the cervix. Malaysian J Pathol, 33, 83-7.
5. Doorbar J (2005). The papillomavirus life cycle. J Clin Virol, 32, 7-15
6. Eleut Jr.ério J Jr, Giraldo PC, Gonçalves AK, et al (2007). Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus. Acta Obstet Gynecol Scand, 86, 94-8.
7. Klaes R, Friedrich T, Spitkovsky D, et al (2001). Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer, 92, 276-84.
8. Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA (2007). p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol, 31, 33-43
9. Kurshumliu F, Thorns C, Gashi-Luci L (2009). p16INK4A in routine practice as a marker of cervical epithelial neoplasia. Gynecol Oncol, 115, 127-31
10. Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J (2009). p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. Diagn Pathol, 4, 22-?.
11. Lim GCC, Rampal S, Halimah Y (Eds) (2008). Cancer Incidence in Peninsular Malaysia 2003-2005. The Third Report of the National Cancer Registry. National Cancer Registry, Ministry of Health Malaysia. Kuala Lumpur.
12. Missaoui N, Trabelsi A, Hmissa S, et al (2010). p16INK4A overexpression in precancerous and cancerous lesions of the uterine cervix in Tunisian women. Pathol Res Pract, 206, 550-5
13. Murphy N, Ring M, Heffron CC, et al (2005). p16INK4A, CDC6,and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol, 58, 525-34
14. Nishino HT, Tambouret RH, Wilbur DC (2011). Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Cancer Cytopathol, 119, 219-27
15. Reuschenbach M, Vinokurova S, von Knebel Doeberitz M (2011). HPV-associated carcinomas of the female genital tract Molecular mechanisms of development. Pathologe, 32, 451-60.
16. Rodríguez AC, Schiffman M, Herrero R, et al (2008). Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst, 100, 513-7
17. Schiffman M, Wentzensen N, Wacholder S, et al (2011). Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst, 103, 368-83
18. Sherr CJ, Roberts JM (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev, 18, 2699-711
19. Stanley M (2010). Pathology and epidemiology of HPV infection in females. Gynecol Oncol, 117, 5-10
20. Syrjänen K (2011). Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. Eur J Gynaecol Oncol, 32, 17-33
21. Ukpo OC, Flanagan JJ, Ma XJ, et al (2011). High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol, 35, 1343-50.
22. Van Niekerk D, Guillaud M, Matisic J, et al (2007). p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing. Gynecol Oncol, 107, 233-40
23. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9